key: cord-0811993-1a5oy6fr
authors: Weidenbacher, Payton A.-B.; Waltari, Eric; de los Rios Kobara, Izumi; Bell, Benjamin N.; Pak, John E.; Kim, Peter S.
title: Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade
date: 2022-01-25
journal: bioRxiv
DOI: 10.1101/2022.01.24.477625
sha: a3535b63d65078f85bb1de6a43005d4c0654ea1a
doc_id: 811993
cord_uid: 1a5oy6fr

All but one of the authorized monoclonal antibody-based treatments for SARS-CoV-2 are largely ineffective against Omicron, highlighting the critical need for biologics capable of overcoming SARS-CoV-2 evolution. These mostly ineffective therapeutic antibodies target epitopes that are not highly conserved. Here we describe broad-spectrum SARS-CoV-2 inhibitors developed by tethering the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), to antibodies that are known to be non-neutralizing, but which target highly conserved epitopes in the viral spike protein. These inhibitors, called Receptor-blocking conserved non-neutralizing Antibodies (ReconnAbs), potently neutralize all SARS-CoV-2 variants of concern (VOC), including Omicron. Neutralization potency is dependent on both the binding and inhibitory ReconnAb components as activity is lost when the linker joining the two is severed. In addition, a bifunctional ReconnAb, made by linking ACE2 to a bispecific antibody targeting two non-overlapping conserved epitopes, defined here, shows sub-nanomolar neutralizing activity against all VOCs, including Omicron. Given their conserved targets and modular nature, ReconnAbs have the potential to act as broad- spectrum therapeutics against SARS-CoV-2 and other emerging pandemic diseases.

The emergence of the Omicron variant has rendered six of the seven 1-9 clinically available monoclonal antibodies (mAbs) essentially ineffective against SARS-CoV-2 -only sotrovimab retains robust neutralizing activity against Omicron 10, 11 . These clinical mAbs all target the receptor binding-domain (RBD) 1-9 of the spike protein and were selected for their neutralizing potency against Wuhan-Hu-1 SARS-CoV-2. The six mAbs besides sotrovimab target non-conserved (variable) regions of the RBD 4,12-18 and prevent interaction with its receptor, human angiotensin converting enzyme 2 (ACE2) 16, [19] [20] [21] . Sotrovimab, a derivative of the mAb S309 [22] [23] [24] [25] , was initially isolated from a SARS-CoV-1 survivor, so its epitope in the RBD is more highly conserved, 9 although in vitro escape mutations have been identified 14 .

The spike protein is large (~450 kDa as a trimer), and contains extensive regions that are extremely highly conserved (Fig. 1A) [26] [27] [28] [29] . Some residues on the spike that are distant from the RBD have near-perfect sequence identity within related coronaviruses (Fig. 1B) 30, 31 . Presumably, these regions are highly conserved because they are required for viral activity (e.g., membrane fusion) 32 . While the spike protein of Omicron has a much larger mutational profile than that of previous variants of concern (VOCs) 33 , with 36 total mutations, 15 being in the RBD 11, 34, 35 , the highly-conserved epitopes remain largely unaltered (Fig. 1) . 11, 34, 35 In other viral spike proteins, for instance influenza hemagglutinin [36] [37] [38] [39] [40] [41] , highly conserved epitopes outside of the receptor-binding region are targets of potent broadly neutralizing antibodies (bnAbs). However, despite the heightened interest sparked by the global pandemic, the search for bnAbs against betacoronaviruses has been largely disappointing. While one conserved helical epitope at the base of the spike protein has been shown to elicit rare mAbs with relatively broad neutralizing activity, their potency is often weaker than RBD-directed neutralizing Abs [42] [43] [44] [45] . Further, neutralizing N-terminal domain (NTD) 46, 47 antibodies have been identified, but their epitopes are not highly conserved.

Indeed, available evidence suggests that conserved regions outside the RBD generally elicit non-neutralizing mAbs 43, [48] [49] [50] [51] [52] [53] [54] . We hypothesized that we could generate potent, broadspectrum inhibitors by modifying existing non-neutralizing antibodies which target highly conserved epitopes on the spike protein to also contain a receptor-blocking component. Due to the conservation of their epitopes, such inhibitors would potentially be broadly neutralizing.

Here we introduce Receptor-blocking conserved non-neutralizing Antibodies, (ReconnAbs -pronounced recon-abs), a novel class of therapeutic proteins in which non-neutralizing Sequence identity for all residues in the SARS-CoV-2 spike protein compared to a set of 44 related coronavirus spike proteins shows higher conservation in the S2 relative to S1. A value of 1.0 means perfect identity across all compared coronavirus proteins. RBD and NTD domains of SARS-CoV-2 spike are labeled on top, S1 and S2 domains are labeled on bottom. antibodies that target highly conserved, non-RBD epitopes, are tethered to the ACE2 receptor, which otherwise has low intrinsic affinity and neutralizing potency. The cross-reactive, nonneutralizing antibodies were identified in a two-step process. First, we analyzed the phylogenetic trees of a collection of SARS-CoV-2 antibodies and eliminated those that are likely to bind the RBD. Then, similar to the development of sotrovimab, 9 we determined which of these non-RBD antibodies bound to the SARS-CoV-1 spike protein. We predict that ReconnAbs will have both increased potency, due to the increase in effective concentration of each component 55 , as has been shown previously for non-neutralizing antibody fusions 56 , but more importantly, increased broad-spectrum activity by targeting highly conserved, non-RBD epitopes on spike. ReconnAbs show neutralizing activity against all SARS-CoV-2 VOCs tested, including Omicron. Further, a bispecific ReconnAb containing two non-neutralizing antibodies with non-overlapping epitopes fused to ACE2 confers sub-nanomolar neutralization against all VOCs tested. Our findings reveal the benefit of repurposing highly cross-reactive, non-neutralizing antibodies to create a new class of broad-spectrum anti-viral agents.

To first profile the landscape of non-neutralizing antibodies, we produced a library of SARS-CoV-2 spike-binding antibodies not directed against the RBD. To ensure library diversity, we first curated the publicly available SARS-CoV-2 antibody repository CoV-AbDab 46,57-60 for sequences specifically from COVID-19 convalescent donors that bound to the spike protein outside of the RBD. From this limited set of 696 antibody sequences, we generated phylogenetic trees for both the antibody heavy chain (HC) and light chain (LC). We constructed phylogenies using amino acid sequences of full-length V-genes and the CDR3 region. We also included one allele of each germline V-gene into the phylogenies to provide context for germline diversity of the antibody dataset.

We compiled non-RBD-binding antibodies, focusing specifically on the clustering of the non-RBD-binding sequences within the HC phylogenetic tree ( Fig. 2A) . We identified distinct clusters on the heavy/light chain phylogenetic trees and chose 48 diverse sequences spread throughout the tree ( Fig. 2A and Supplementary Fig. 1) . These included at least one antibody sequence from all clusters containing at least four or more non-RBD-binding antibodies. The sequences we chosen based on their HC sequences also showed diversity in the LC phylogenetic tree ( Supplementary Fig. 1 ). These 48 clones display a range of CDRH3 and CDRL3 lengths ( To determine which of these 48 non-RBD-binding antibodies target highly conserved epitopes, we used binding to the SARS-CoV-1 spike as a surrogate for epitope conservation. We designed the 48 scFvs constructs by fusing the antibody HC and LC variable regions to the yeast surface protein Aga2p 61-63 to enable yeast-surface display. To profile the scFv panel, we optimized production of biotinylated SARS-CoV-2 and other human coronavirus (hCoV) spike proteins (Supplementary Fig. 2A -D) and produced biotinylated versions of the SARS-CoV-2 and SARS-CoV-1 spike proteins. These were used to probe the yeast library by fluorescence flow cytometry (Fig. 3A) . The complete 48-member library showed robust (82%; Fig 3A) staining with the SARS-CoV-2 spike, consistent with the original antibody collection having been isolated from SARS-CoV-2 convalescent donors. The library had reduced (21%; Fig 3A) staining with the SARS-CoV-1 spike. Consistent with the intention of the library, no clones bind to the RBD of SARS-CoV-2 (Fig. 3A) .

Having identified 48 antibodies that bind outside the RBD, we next selected those that bind to highly conserved regions of the spike protein. To do this, we used fluorescence-activated cell sorting (FACS) 64 with the SARS-CoV-1 spike protein as bait and identified ten sequences.

We confirmed that the corresponding full-length IgG antibodies ( Supplementary Fig. 3 ) bind to both SARS-CoV-2 and SARS-CoV-1 spike proteins by ELISA ( Supplementary Fig. 4 ). Of the ten, seven clones were strong SARS-CoV-1 binders, confirmed by biolayer interferometry (BLI) ( and 5). Consistent with previous reports 4,57-60 , these antibodies were non-neutralizing in our assay ( Supplementary Fig. 6 ).

We used BLI to characterize the epitopes of these seven antibodies in a binding competition assay. We loaded each antibody onto either SARS-CoV-2 or SARS-CoV-1 spike proteins, and then we tested for subsequent binding of each of the other antibodies (Fig. 3C) . The results suggest that there are five primary epitopes, of which four are in a partially overlapping supersite (Fig. 3C ) -likely corresponding to the extensive, continuous patch of highly conserved residues on the spike protein surface (Fig. 1A) . Two sets of antibodies had identical epitopesthe pair 60 of COVA2-14 and COVA2-18, and the pair of CV27 and COV2-2147. This result is consistent with the phylogeny, which shows the antibodies in the two pairs clustered very closely together ( Fig. 2A and Supplementary Fig. 1 ). The identification of five unique epitopes from the seven selected antibodies highlights the diversity in the initial starting library.

We selected five antibodies, one from each described epitope (Fig. 3D) , and converted these non-neutralizing, cross-reactive antibodies into ReconnAbs by fusion to the ACE2 ectodomain, as the receptor-blocking component of the ReconnAb design. We designed the linker to be long enough to allow for simultaneous binding of both ACE2 to the RBD and the scFv, regardless of epitope, to the spike S2 domain ( Fig. 4A and Supplementary Fig. 7) . We joined the C-terminus of the scFv to the N-terminus of ACE2, because the N-terminal residue of the ACE2 ectodomain is adjacent to the SARS-CoV-2 RBD when bound. We also incorporated within the linker a hexa-histidine tag for purification and a TEV protease site to enable assessment of ReconnAb activity when its binding and inhibitory components are separated ( Fig. 4A and Supplementary Fig. 7) . We anticipated that ReconnAbs would bind to both a highly conserved site on the spike protein and simultaneously to the RBD through the ACE2 domain ( Fig 4B) .

However, if cleaved at the TEV site, the intrinsically low-affinity ACE2 domain would not benefit from the affinity of the non-neutralizing antibody (Fig. 4B ).

We expressed and purified the five ReconnAbs and used gel electrophoresis to confirm that TEV cleavage separated the ACE2 and scFv components (Fig. 4C) . BLI experiments showed that TEV cleavage of the ReconnAb proteins reduced binding to both SARS-CoV-2 and SARS-CoV-1 spike proteins (Fig. 4D) , consistent with the lower affinity of monomeric ACE2 65 . We then investigated the ability of the ReconnAbs to block ACE2 binding to the SARS-CoV-2 spike protein.

ACE2 competition is often used as a surrogate for neutralization, as preventing ACE2 binding prevents the virus from interacting with target cells 66 . Indeed, uncleaved ReconnAbs show substantial interference with binding of an Fc version of human ACE2 (hFc-ACE2) whereas TEVcleaved ReconnAbs do not (Fig. 4E) . We next investigated if ReconnAbs were able to neutralize lentiviral pseudoviruses corresponding to the SARS-CoV-2 VOCs and found that all ReconnAbs neutralized all VOCssome showing nanomolar potency against Omicron (Fig. 5 ). Consistent with its lower affinity ( Fig.   3D ), COV2-2143-ACE2 had the weakest neutralization of the tested ReconnAbs (Fig. 5 ). COV2-2449-ACE2 showed the least deviation in neutralization potency between variants, consistent with its epitope being the most highly conserved (Supplementary Fig. 4 and 5) . Importantly, the TEVproteolyzed versions of the ReconnAbs did not confer the same neutralizing potency as their uncleaved counterparts (Fig. 5) , demonstrating that the separate components are not working synergistically, but that the tether is essential for the ReconnAb components to work cooperatively.

Two ReconnAbs, CV10-ACE2 and COV2-2449-ACE2, were of particular interest as they showed broad-spectrum neutralization (Fig. 5 ) and did not have overlapping epitopes (Fig. 3C) .

We postulated that a bifunctional IgG-ReconnAb containing both CV10 and COV2-2449 would make viral escape even less likely. To produce a bifunctional IgG-ReconnAb, we utilized the CrossMAb platform [67] [68] [69] and tethered ACE2 to the LC of only one of the IgG arms (Fig. 6A, B ).

This allows, as with the scFv-ACE2 fusions, that the stoichiometry be only a single ACE2 per ReconnAb, such that ACE2 remains monovalent before and after TEV-cleavage.

We expressed and purified the CV10-2449-ACE2-CrossMAb (Fig. 6B ) and found that it bound to SARS-CoV-2 as expected ( Fig 6C) . As well, the uncleaved CrossMAb competed substantially with ACE2 ( Supplementary Fig. 8 ). Dependent on the presence of the tether, the CV10-2449-ACE2-CrossMAb neutralized all SARS-CoV-2 VOCs, including Omicron, at subnanomolar concentrations (Fig. 6D ). Taken together, the results described here lay a foundation for the development ReconnAbs as a novel class of broadly neutralizing therapeutics. 

Traditionally, the discovery of therapeutic biologics against infectious diseases has focused on identifying agents with neutralizing activity. We demonstrate here using ReconnAbs, that cross-reactive, non-neutralizing antibodies -which have been often largely overlooked -can be powerful reagents in the creation of potent, broad-spectrum anti-viral agents. Improvements could also be made to the conserved, non-neutralizing antibodies. Our library of SARS-CoV-2 non-RBD antibodies was derived from sequences early in the COVID-19 pandemic, which is relatively small in scope. The library does not contain, for instance, any vaccine-derived antibodies, which are known to include cross-reactive, non-neutralizing antibodies 49 . Future iterations of this work could start with much larger libraries 57 , with the potential to identify antibodies and/or nanobodies that target the most highly conserved epitopes and that are least likely to undergo mutational escape 79 . Although we have focused on non-neutralizing antibodies, neutralizing antibodies that bind to conserved epitopes might also be useful as the conserved component of ReconnAbs. Other features like linkage locations and length, fusion partners, and modifications to the Fc domains can be tuned in subsequent ReconnAb designs, and will likely play an important role in their future conversion to therapeutics [23] [24] [25] .

Compared to neutralizing epitopes, highly conserved, non-neutralizing epitopes are less likely in theory to be subject to immune pressure since their mutations do not affect the ability of the virus to infect cells. Omicron provides strong evidence that SARS-CoV-2 viral evolution responds to immune pressure by mutating neutralizing epitopes ( Fig.1) 

A library of antibodies directed against SARS-CoV-2 Spike (S) protein was developed using paired antibody sequences, meaning antibody sequences for which the heavy and light chain are both known, from the Coronavirus Antibody Database, CoV-AbDab 57 . All antibody sequences from convalescent COVID-19 donors which had been deposited before July 9 th 2021, were inserted into a table, categorized by their binding to the SARS-CoV-2 RBD portion of the spike protein or to a non-RBD portion of SARS-CoV-2 spike. Antibodies which were cataloged for non-RBD binding were preferentially identified, resulting in a total of 385 paired antibody sequences. For these non-RBD binding antibodies, the amino acid sequences of the corresponding heavy chain and light chain V-genes and CDR3 regions, already compiled from the Coronavirus Antibody Database, were imported into Geneious Prime v2021.1.1 (a bioinformatics software; geneious.com). Using Geneious Prime, the heavy chain sequences and light chain sequences were separately analyzed to produce phylogenetic trees. For these phylogenetic trees, RBD binding antibodies were also included to ensure selection of antibody sequences that were both non-RBD binding and clearly distinct from RBD-binding sequences. 

Sequences:

Hexa-His tag 

Supplementary Figure 1 -The non-RBD library was selected to prioritize diversity. A phylogenetic tree generated using Geneious Prime of 436 light chain sequences from a curated library of 696 anti-SARS-COV-2 spike antibody sequences. Labels same as Fig. 1 . Germline alleles are not shown. Antibodies denoted with names were cross-reactive for SARS-CoV-1.

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. bioRxiv

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Potently neutralizing and protective human antibodies against SARS-CoV-2

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Comprehensive mapping of mutations in the SARS-CoV-2 receptorbinding domain that affect recognition by polyclonal human plasma antibodies

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

Enhanced antibody half-life improves in vivo activity

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

ConSurf: Using evolutionary data to raise testable hypotheses about protein function

ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules

Calculating evolutionary conservation in sequence and structure of proteins and nucleic acids

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

MUSCLE: multiple sequence alignment with high accuracy and high throughput

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 variants, spike mutations and immune escape

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains

Broadly neutralizing antibodies against influenza virus and prospects for universal therapies

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

Antibody-guided vaccine design: Identification of protective epitopes

Toward a Universal Influenza Virus Vaccine: Prospects and Challenges

Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope

Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern

Structural basis for broad coronavirus neutralization

Broad betacoronavirus neutralization by a stem helix-specific human antibody

A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD

Immunological imprinting of the antibody response in COVID-19 patients

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

Immune imprinting and SARS-CoV-2 vaccine design

Breadth and function of antibody response to acute SARS-CoV-2 infection in humans

Broad neutralization of SARS-related viruses by human monoclonal antibodies

On the attribution and additivity of binding energies

Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2

The coronavirus antibody database

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Highly avid magnetic bead capture: An efficient selection method for de novo protein engineering utilizing yeast surface display

Yeast surface display for protein engineering and characterization

Yeast surface display for screening combinatorial polypeptide libraries

Fluorescence-activated cell sorting

Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity

A SARS-CoV-2 surrogate virus neutralization test based on antibodymediated blockage of ACE2-spike protein-protein interaction

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

Engineering therapeutic bispecific antibodies using CrossMab technology

The use of CrossMAb technology for the generation of bi-and multispecific antibodies

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

High affinity modified ACE2 receptors prevent SARS-CoV-2 infection

Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein

A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Both Neutralizing and Non-neutralizing Human H7N9 Influenza Vaccine-induced Monoclonal Antibodies Confer Protection

A) A schematic representation of constructs tested for expression. 6 hCoV spike proteins, either FL or truncated, tested with 4 different C-terminal trimerization domains and tags. ∆C truncations shown in the middle, SARS-CoV-2 spike numbering. (B) linkers tested. For those without Avi tags, the underlined portions were removed. (C) (top) BLI binding responses from isolated Expi supernatants binding to His 1K octet tips

Influenza hemagglutinin used as a positive control, mock transfection as a negative control. (D) Yield determined for full length 2P hCoV constructs containing the GCN4-Avi-His tag from a duplicate experiment of 100 mL transfections

Supplementary Figure 3 -SDS-page analysis of of IgG proteins made from clones identified in the SARS-CoV-1 FACS sorts. MW ladders are in the left-most lanes of the two gels

Biotinylated hCoV antigens were plated and dilutions of IgGs were tested for binding. Normalized A450 calculated by adjusting for pathlength. Except for COV2-2490

Supplementary Figure 5 -BLI binding for the 7 identified SARS-CoV-1 cross-reactive clones against MERS (left) or OC43 (right) spike proteins. Only COV2-2449 shows any binding affinity for MERS or weakly to OC43 spike proteins

Supplementary Figure 6 -Single dilution (100 nM) neutralization against SARS-CoV-2 Wuhan-Hu-1 for the 7 identified cross-reactive antibodies. All antibodies show no neutralization at a high concentration of 100nM

Supplementary Figure 7 -The linker used to tether ACE2 to either the C-terminus of the scFv or C-terminus of the COV2-2449 LC. The linker was designed to contain a Hexa-His tag for purification and a TEV site to facilitate proteolysis

Supplementary Figure 8 -Relative hFc-ACE2 binding to SARS-CoV-2 spike protein which has been pre-associated with 200 nM CV10-2449-XMAb (left) or the TEV cleaved form (right)

We thank J. Bloom and A. Greaney